Boston Scientific accounts are for healthcare professionals only.
250,000+ patients
have received DBS therapy1 and 96% would choose DBS again.2
Ways to refer
Our experts can answer your questions and guide you throughout the referral process.
Streamlined referral process
We simplify the referral process, ensuring a seamless experience for you and your patients.
Patient resources and data
Access patient education support and review clinical outcomes in DBS.
Connect with your DBS Specialist Liaison
Our most valuable support service is the partnership offered through our DBS Specialist Liaison Program, which provides tools and resources to assist you.
Ways to refer your patients
Clinical data and patient tools
Resources to help your patients learn more about their treatment options.
Boston Scientific sponsored the first double-blinded, sham-controlled study on DBS for PD patients which demonstrated:3,4
6 more hours of "ON-time" daily
51% improvement in UPDRS III at 1 year
Sustained motor improvement for at least 5 years
A prospective multicenter international registry for ET showed:5
A mean increase of 9 hours/day without tremor at one year
12 months of clinically significant improvement in Quality of Life (QoL)
REFERENCES:
1. Johnson KA, et al. Proceedings of the 11th Annual Deep Brain Stimulation Think Tank: pushing the forefront of neuromodulation with functional network mapping, biomarkers for adaptive DBS, bioethical dilemmas, AI-guided neuromodulation, and translational advancements. Frontiers in Human Neuroscience. 2024 Feb 21;18:1320806. doi: 10.3389/fnhum.2024.1320806. (250,000 patients implanted)
2. Knoop CD, Kadish R, Hager K, Park MC, Loprinzi PD, LaFaver K. Bridging the gap in patient education for DBS surgery for Parkinson’s disease. J Parkinson’s Dis. 2017;2017:9360354. doi:10.1155/2017/9360354.
3. Vitek JL, et al. Subthalamic nucleus deep brain stimulation with a multiple independent constant current controlled device in Parkinson’s disease (INTREPID): A multicentre, double-blind, randomised, sham-controlled study. The Lancet Neurology. 2020;19(6):491-501. https://doi.org/10.1016/S1474-4422(20)30108-3
4. Vitek JL, et al. A five-year follow-up of a prospective, double-blinded, multi-center randomized controlled trial evaluating deep brain stimulation with a new multiple source, constant current rechargeable system for treatment of Parkinson’s disease (INTREPID). Annual Meeting of the American Academy of Neurology, Seattle, WA. April 24-26, 2022.
5. Deuschl G et al, Improvement in Quality of Life and motor function: Real-world, Prospective Study of Directional DBS Systems, AAN meeting 2023.
INDICATION FOR USE:
The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:
- Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
- Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
- Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.
- Bilateral stimulation of the ventral intermediate nucleus (VIM) of the thalamus for the suppression of disabling upper extremity tremor in adult essential tremor patients whose tremor is not adequately controlled by medications and where the tremor constitutes a significant functional disability.
The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:
- Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.
Contraindications, warnings, precautions, side effects: The Boston Scientific Deep Brain Stimulation (DBS) Systems or any of its components, are contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific DBS System without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia or Vercise Genus or Vercise Genus Mixed System with M8 Adapter or Vercise DBS Lead-Only System (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately. Refer to the Instructions for Use provided with the Boston Scientific DBS Systems or BostonScientific.com for potential adverse effects, warnings, and precautions prior to using this product. Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.